CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on February 6, 2024
TELOMIR
PHARMACEUTICALS, Inc.
900 West Platt Street, Suite 200
Tampa, Florida 33606
February 6, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tara Harkins, Lynn Dicker, Jimmy McNamara, and Joe McCann
| Re: | Telomir Pharmaceuticals, Inc. | |
| Registration Statement on Form S-1 | ||
| Filed November 14, 2023 | ||
| File No. 333-275534 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Telomir Pharmaceuticals, Inc., hereby requests that the above-referenced Registration Statement on Form S-1 be declared effective at 4:30 p.m., Eastern Standard Time, on Thursday, February 8, 2024, or as soon as practicable thereafter. The Registrant respectfully requests that you notify Neda Sharifi and Curt Creely of Foley & Lardner LLP of such effectiveness by a telephone call to (904) 359-8719 or (813) 225-4122.
| Very truly yours, | ||
| TELOMIR pharmaceuticals, Inc. | ||
| By: | /s/ Dr. Christopher Chapman, Jr. | |
| Dr. Christopher Chapman, Jr. | ||
| Chief Executive Officer | ||